In another lightning round JP Morgan interview, editor-in-chief Jonah Comstock caught up with Sam Deutsch, CEO of Nutcracker Therapeutics, to talk briefly about the company’s lead asset for cervica
Vir Biotechnology made headlines in 2021 for its work with GlaxoSmithKline on a treatment for COVID-19, and again in 2022 for its work with the US government on influenza.
Generative AI – large language models, or LLMs, like ChatGPT – has the potential to revolutionise almost any knowledge industry, and pharma is no exception.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.